Chemed Corporation $CHE Shares Purchased by Vest Financial LLC

30 Apr 2026, 21:19 by Renee Jackson · The Cerbat Gem

Vest Financial LLC raised its stake in shares of Chemed Corporation (NYSE:CHE – Free Report) by 20.9% in the 4th quarter, according to its most recent Form 13F filing with the SEC. The fund owned 11,734 shares of the company’s stock after purchasing an additional 2,032 shares during the period. Vest Financial LLC’s holdings in Chemed were worth $5,021,000 at the end of the most recent reporting period.

Several other institutional investors also recently bought and sold shares of the business. Mitsubishi UFJ Trust & Banking Corp boosted its stake in shares of Chemed by 312.0% in the fourth quarter. Mitsubishi UFJ Trust & Banking Corp now owns 6,267 shares of the company’s stock valued at $2,681,000 after purchasing an additional 4,746 shares during the period. M&T Bank Corp grew its position in Chemed by 37.5% in the 4th quarter. M&T Bank Corp now owns 1,137 shares of the company’s stock valued at $487,000 after buying an additional 310 shares in the last quarter. Pictet Asset Management Holding SA boosted its position in shares of Chemed by 5.5% during the 4th quarter. Pictet Asset Management Holding SA now owns 2,195 shares of the company’s stock valued at $939,000 after purchasing an additional 114 shares in the last quarter. UBS Group AG boosted its position in shares of Chemed by 8.4% during the 4th quarter. UBS Group AG now owns 121,482 shares of the company’s stock valued at $51,977,000 after purchasing an additional 9,364 shares in the last quarter. Finally, Abacus FCF Advisors LLC acquired a new position in shares of Chemed in the fourth quarter worth about $5,935,000. 95.85% of the stock is currently owned by hedge funds and other institutional investors.

Chemed Stock Up 0.7%

Chemed stock opened at $423.87 on Thursday. The company’s 50 day simple moving average is $400.23 and its 200 day simple moving average is $426.04. Chemed Corporation has a fifty-two week low of $365.20 and a fifty-two week high of $583.96. The firm has a market capitalization of $6.19 billion, a price-to-earnings ratio of 23.10, a PEG ratio of 1.58 and a beta of 0.49. The company has a debt-to-equity ratio of 0.11, a current ratio of 0.85 and a quick ratio of 0.83.

Chemed (NYSE:CHE – Get Free Report) last posted its quarterly earnings data on Thursday, April 23rd. The company reported $5.65 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $5.30 by $0.35. Chemed had a net margin of 10.23% and a return on equity of 27.18%. The company had revenue of $657.51 million for the quarter, compared to the consensus estimate of $659.22 million. During the same period last year, the company earned $5.63 earnings per share. The firm’s revenue was up 1.6% compared to the same quarter last year. Chemed has set its FY 2026 guidance at 24.000-24.75 EPS. As a group, sell-side analysts anticipate that Chemed Corporation will post 22.31 EPS for the current year.

Chemed Dividend Announcement

The company also recently announced a quarterly dividend, which was paid on Friday, March 13th. Investors of record on Monday, February 23rd were issued a dividend of $0.60 per share. This represents a $2.40 dividend on an annualized basis and a yield of 0.6%. The ex-dividend date was Monday, February 23rd. Chemed’s payout ratio is presently 13.08%.

Insiders Place Their Bets

In related news, CEO Kevin J. Mcnamara sold 2,000 shares of the business’s stock in a transaction on Thursday, March 12th. The shares were sold at an average price of $403.18, for a total transaction of $806,360.00. Following the transaction, the chief executive officer directly owned 93,719 shares in the company, valued at approximately $37,785,626.42. The trade was a 2.09% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Insiders own 3.33% of the company’s stock.

Analysts Set New Price Targets

A number of research firms have issued reports on CHE. Jefferies Financial Group cut shares of Chemed from a “buy” rating to a “hold” rating in a research note on Thursday, January 22nd. Weiss Ratings lowered shares of Chemed from a “hold (c-)” rating to a “sell (d+)” rating in a report on Monday, April 13th. Oppenheimer decreased their price objective on shares of Chemed from $580.00 to $500.00 and set an “outperform” rating on the stock in a report on Friday, February 27th. Zacks Research raised shares of Chemed from a “strong sell” rating to a “hold” rating in a report on Monday. Finally, Royal Bank Of Canada increased their price objective on shares of Chemed from $422.00 to $436.00 and gave the stock a “sector perform” rating in a report on Monday. Two analysts have rated the stock with a Buy rating, three have given a Hold rating and one has assigned a Sell rating to the company. According to data from MarketBeat, the stock currently has an average rating of “Hold” and a consensus price target of $501.50.

Get Our Latest Research Report on Chemed

Chemed Profile

(Free Report)

Chemed Corporation is a diversified provider of essential home services and healthcare solutions in the United States. Headquartered in Cincinnati, Ohio, the company operates through two principal business segments—Roto-Rooter and Vitas Healthcare. Since its founding in 1974, Chemed has built a reputation for reliability and expertise, serving both residential and commercial customers across a broad range of markets.